Drugs / STR-324
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03430232 | Feb → Nov 2018 | — | Stragen France | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04582786 | Dec 2020 → Jan 2022 | — | Alaxia SAS | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STR-324 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03430232 ↗ |
| Route | Intravenous | “Short infusion of a solution for intravenous administration” NCT03430232 ↗ |